ANVISA DIFA and CADIFA requirements govern how active pharmaceutical ingredients (APIs) for new, innovative, generic and similar medicines are assessed in Brazil. Under RDC 359/2020, the API holder submits a dossier (DIFA), and ANVISA issues a Letter of Suitability (CADIFA) once the dossier is approved. Because medicine registration depends on a valid CADIFA, these ANVISA API regulations shape which APIs can supply the Brazilian market.
This article covers scope, documentation, the DIFA and CADIFA submission process and the link to GMP.
What Are DIFA and CADIFA in Brazil?
The DIFA is the dossier a holder submits for an API, and the CADIFA is the letter ANVISA issues once that dossier is approved. CADIFA requirements in Brazil therefore start with a complete DIFA.
The DIFA contains the API’s administrative and quality documents, from the manufacturing process to specifications and stability. The CADIFA is ANVISA’s confirmation that the DIFA meets RDC 359/2020. The letter records the holder, manufacturing sites, specification, packaging, storage conditions and retest period or shelf life.
ANVISA assesses both sets of documents before issuing the letter. The DIFA holder then becomes the CADIFA holder.
Which APIs Require DIFA and CADIFA?
DIFA requirements in Brazil apply to APIs used in new, innovative, generic and similar medicines. These ANVISA requirements for active pharmaceutical ingredients come from RDC 359/2020. They cover synthetic and semi-synthetic APIs.
RDC 359/2020 does not cover atypical APIs, or APIs used in notified products or in biological, herbal, traditional herbal, specific or dynamized medicines.
Manufacturer location makes no difference. Foreign and domestic manufacturers follow the same rules. What matters is the DIFA holder. This is the company that knows the whole manufacturing process and is responsible for it, from the starting material onward.
ANVISA DIFA Documentation and Technical Requirements
The ANVISA API dossier (DIFA) combines administrative documents with quality documents organized.
| Component | What to provide |
| Administrative information |
API form and declarations of the holder’s responsibilities to ANVISA and the medicine applicant. Also a TSE risk assessment or a declaration that no human or animal origin raw materials are used.
|
| Manufacturing process and controls |
Names, addresses and responsibilities of manufacturing and quality-control units, including subcontractors. Also the synthesis route, process narrative, critical steps and validation.
|
| Specifications and analytical methods |
API specification, analytical methods, their validation and analysis of at least three batches.
|
| Impurity profile and stability |
Discussion of potential impurities. Stability studies with storage conditions and retest period or shelf life.
|
| Supporting documentation |
ICH guides such as Q1A, Q3A, Q3D, Q6A, Q11 and M7. ANVISA may request further tests.
|
CADIFA Application and Assessment Process
The CADIFA application process runs from system registration to submission, assessment, responses and issuance. Following are steps to obtain CADIFA approval in Brazil.
Step 1: Company registration and Solicita access.
To use Solicita, a company needs a CNPJ registered with ANVISA and a security manager.
Step 2: DIFA holder registration.
A holder without a CNPJ sends the registry form and receives a DIFA Holder Number (DHN) and Authorized User Number (AUN).
Step 3: Submission.
The holder submits the DIFA. An associated request is linked to a medicine registration or post-registration and follows the Law 6.360/1976 deadlines. A non-associated request follows an expression of interest or a public call.
Step 4: Assessment.
ANVISA’s API coordination (COIFA) assesses the administrative and quality documents.
Step 5: Requirements and deficiencies.
ANVISA sends requirements, approval or rejection directly to the holder. A rejection can be reconsidered under the appeals rules.
Step 6: Issuance.
ANVISA issues the CADIFA to the holder, unless it finds GMP non-compliance.
DIFA Submission Requirements for Foreign API Manufacturers
Foreign API manufacturers can submit their DIFA directly to ANVISA without appointing a Brazilian representative. However, ANVISA recommends having a local Brazilian representative to facilitate the process.
A holder without a CNPJ registers through the registry form with an authorization letter and receives a DHN and an Authorized User Number. The authorized user (security manager) acts for the holder in ANVISA’s systems. ANVISA suggests naming at least two security managers.
The holder controls the dossier. Where confidentiality applies, the quality documents are split into an open part for the medicine applicant and a restricted part. The applicant gets the CADIFA with the holder’s access declaration. ANVISA sends requirements and decisions directly to the holder.
All API and intermediate manufacturing locations should be included in the CADIFA. ANVISA recommends one registration per company or group, with a separate security manager for each site if necessary.
DIFA and CADIFA Changes, Maintenance and Regulatory Updates
Approved DIFAs are maintained through four categories of change. The CADIFA Manual also provides procedures for similar DIFAs, shared CADIFAs, optimized assessment and holder changes.
Categories of changes to an approved DIFA
Changes to the API manufacturing process or specifications are classified into four categories:
- Annual notification
- Immediate notification
- Minor change
- Major change
Notifications need no prior ANVISA opinion. Minor and major changes must await it, unless ANVISA is silent for 60 or 180 days respectively. A revised CADIFA follows when CADIFA content changes, or for any major change.
Other procedures under the CADIFA Manual
- Change of CADIFA holder: Applies to corporate transactions (spin-off, merger, incorporation) and commercial transactions that transfer assets. It covers only cases where the API’s conditions and technical-sanitary characteristics stay the same.
- Similar DIFA: A holder can apply for a separate CADIFA for the same API when there are differences, for example, an alternative process, site or quality grade that cannot be handled as a change.
- Use of one CADIFA by another (Shared CADIFA): A secondary CADIFA can refer to an already approved primary CADIFA for the starting material or intermediate used in API manufacturing.
- Optimized assessment: ANVISA may offer a simplified assessment for an API when its quality grade is identical to one already approved by an equivalent foreign regulatory authority. It is limited to those cases and is not automatic recognition of a foreign approval. ANVISA publishes a checklist for it.
Holders must keep an approved DIFA aligned with ANVISA’s requirements, and those requirements can change. At Artixio, we built our regulatory intelligence platform, Qurious RI, to help with this. Its Impact Overview feature shows how a new guideline or announcement affects a company’s existing SOP and what action is needed.
Relationship Between CADIFA, GMP and Pharmaceutical Product Registration
The CADIFA confirms dossier suitability and site GMP compliance. Neither is a product registration.
| Instrument | What it confirms |
| DIFA | The API’s administrative and quality dossier |
| CADIFA | ANVISA’s finding that the DIFA is adequate |
| CBPF (API GMP certificate) |
GMP compliance of the manufacturing establishment
|
| Product registration | Authorization of the finished medicine |
API manufacturers must comply with Good Manufacturing Practices (GMP). If ANVISA finds any GMP non-compliance, it will not issue the CADIFA.
When applying for medicine registration in Brazil, the applicant must submit:
- An authorization letter from the DIFA holder.
- A GMP compliance statement.
- The application number for the API GMP certificate.
Medicine registration is granted only when the API has a valid GMP certificate and CADIFA.
Conclusion
Foreign API manufacturers planning to enter the Brazilian pharmaceutical market must understand and comply with ANVISA’s DIFA and CADIFA requirements. Proper dossier preparation, GMP compliance and timely regulatory submissions are essential for obtaining and maintaining CADIFA approval and supporting the registration of medicines in Brazil. Manufacturers should also monitor ANVISA’s regulatory updates to ensure continued compliance with the latest requirements
For support with ANVISA API regulations, DIFA preparation or CADIFA submissions, reach out to info@artixio.com. For regulatory support in Brazil, explore Artixio’s Brazil regulatory affairs services. To follow regulatory updates and see how they affect your SOPs, request a Qurious RI demo.
FAQs
Q1. Is a DIFA the same as a CADIFA?
No. The DIFA is the API dossier the holder submits. The CADIFA is the letter ANVISA issues to the holder if the DIFA is approved.
Q2. Can a foreign API manufacturer submit a DIFA directly to ANVISA?
Yes. The DIFA must be sent by its holder, and foreign holders follow the same submission route as Brazilian holders. A holder without a Brazilian CNPJ registers through ANVISA’s DIFA holder registry form. ANVISA also suggests, without requiring it, representation by a Brazilian branch or authorized company.
Q3. Which APIs are excluded from DIFA and CADIFA requirements?
Atypical APIs are excluded. So are APIs used in notified products or in biological, herbal, traditional herbal, specific or dynamized medicines.
Q4. Does a CADIFA replace GMP certification?
No. ANVISA does not issue a CADIFA if GMP non-compliance is found, but the API GMP certificate is a separate document. Medicine registration needs both to be valid.
Q5. Do DIFA changes need ANVISA approval before implementation?
It depends on the category. Annual and immediate notifications need no prior opinion. Minor and major changes must await ANVISA’s opinion, unless ANVISA is silent for 60 or 180 days respectively.
